222 related articles for article (PubMed ID: 33783349)
21. Collaborative study for the establishment of Ph. Eur. Biological Reference Preparation for Human tetanus immunoglobulin batch 2.
Stickings P; Tierney R; Hockley J; Rigsby P; Terao E
Pharmeur Bio Sci Notes; 2024; 2024():1-11. PubMed ID: 38533744
[TBL] [Abstract][Full Text] [Related]
22. Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay.
Fuchs F; Minor P; Daas A; Milne C
Pharmeuropa Bio; 2003 Jul; 2003(1):23-50. PubMed ID: 14563307
[TBL] [Abstract][Full Text] [Related]
23. [Factor IX assays in treated hemophilia B patients].
Pouplard C; Jeanpierre E; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Ternisien C; Toulon P; Voisin S; Nougier C;
Ann Biol Clin (Paris); 2019 Feb; 77(1):41-52. PubMed ID: 30799297
[TBL] [Abstract][Full Text] [Related]
24. Establishment of the European Pharmacopoeia Biological Reference Preparation (Ph. Eur. BRP) for hepatitis A vaccine type B (Aventis Pasteur) batch 2.
Buchheit KH; Daas A
Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):95-108. PubMed ID: 12448033
[TBL] [Abstract][Full Text] [Related]
25. Collaborative study for the establishment of the Ph. Eur. BRP batch 1 for anti-vaccinia immunoglobulin.
Fuchs F; Poirier B; Leparc-Goffart I; Buchheit KH
Pharmeuropa Bio; 2005 Sep; 2005(1):13-8. PubMed ID: 16336934
[TBL] [Abstract][Full Text] [Related]
26. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
[TBL] [Abstract][Full Text] [Related]
27. Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).
Fukutake K; Kobayashi T; Sommer JM; Hirakata T
Int J Lab Hematol; 2020 Apr; 42(2):162-169. PubMed ID: 31820573
[TBL] [Abstract][Full Text] [Related]
28. Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.
Ovanesov MV; Williams SC; Nübling CM; Dodt J; Hilger A; Maryuningsih Y; Gray E
Biologicals; 2020 Sep; 67():88-93. PubMed ID: 32847723
[TBL] [Abstract][Full Text] [Related]
29. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
Nummi V; Jouppila A; Lassila R
Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
[TBL] [Abstract][Full Text] [Related]
30. Collaborative study for the calibration of Ph. Eur. Heparin Low-Molecular-Mass for Assay Biological Reference Preparation batch 11.
Terao E; Regourd E
Pharmeur Bio Sci Notes; 2022; 2022():22-31. PubMed ID: 35481431
[TBL] [Abstract][Full Text] [Related]
31. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
32. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
[TBL] [Abstract][Full Text] [Related]
33. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
34. Collaborative study for the establishment of tetanus vaccine (adsorbed) Third International Standard and European Pharmacopoeia Biological Reference Preparation batch no. 2.
Sesardic D; Winsnes R; Rigsby P; Gaines-Das R
Pharmeuropa Spec Issue Biol; 2001 Aug; 2001(1):45-72. PubMed ID: 11705100
[TBL] [Abstract][Full Text] [Related]
35. FIX potency of rFIX-Albumin fusion protein is underestimated by one-stage methods using silica-based APTT reagents.
Rosén S; Bryngelhed P
Haemophilia; 2020 Mar; 26(2):340-345. PubMed ID: 32006459
[TBL] [Abstract][Full Text] [Related]
36. Collaborative study for the establishment of erythropoietin BRP batch 3.
Behr-Gross ME; Daas A; Burns C; Bristow AF
Pharmeuropa Bio; 2007 Dec; 2007(1):49-66. PubMed ID: 18413137
[TBL] [Abstract][Full Text] [Related]
37. Calibration of replacement international standard and European pharmacopoeia biological reference preparation for tetanus toxoid, adsorbed.
Sesardic D; Winsnes R; Rigsby P; Tierney R; Gaines-Das R
Biologicals; 2002 Mar; 30(1):49-68. PubMed ID: 11846430
[TBL] [Abstract][Full Text] [Related]
38. Establishment of Ph. Eur. Bordetella pertussis mouse antiserum Biological Reference Preparation batches 2, 3 and 4.
Morgeaux S; Chagnaud P; Variot P; Le Tallec D; Behr-Gross ME
Pharmeur Bio Sci Notes; 2020; 2020():161-202. PubMed ID: 32788038
[TBL] [Abstract][Full Text] [Related]
39. Collaborative study to establish a new biological reference preparation for prekallikrein activator.
Longstaff C; Behr-Gross ME; Daas A; Lackner F
Pharmeuropa Bio; 2005 Sep; 2005(1):1-12. PubMed ID: 16336933
[TBL] [Abstract][Full Text] [Related]
40. The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX.
Wilmot HV; Rakowski K; Gray E
Int J Lab Hematol; 2020 Dec; 42(6):810-818. PubMed ID: 32638532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
